Literature DB >> 27269948

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

Marjanka K Schmidt1, Frans Hogervorst1, Richard van Hien1, Sten Cornelissen1, Annegien Broeks1, Muriel A Adank1, Hanne Meijers1, Quinten Waisfisz1, Antoinette Hollestelle1, Mieke Schutte1, Ans van den Ouweland1, Maartje Hooning1, Irene L Andrulis1, Hoda Anton-Culver1, Natalia N Antonenkova1, Antonis C Antoniou1, Volker Arndt1, Marina Bermisheva1, Natalia V Bogdanova1, Manjeet K Bolla1, Hiltrud Brauch1, Hermann Brenner1, Thomas Brüning1, Barbara Burwinkel1, Jenny Chang-Claude1, Georgia Chenevix-Trench1, Fergus J Couch1, Angela Cox1, Simon S Cross1, Kamila Czene1, Alison M Dunning1, Peter A Fasching1, Jonine Figueroa1, Olivia Fletcher1, Henrik Flyger1, Eva Galle1, Montserrat García-Closas1, Graham G Giles1, Lothar Haeberle1, Per Hall1, Peter Hillemanns1, John L Hopper1, Anna Jakubowska1, Esther M John1, Michael Jones1, Elza Khusnutdinova1, Julia A Knight1, Veli-Matti Kosma1, Vessela Kristensen1, Andrew Lee1, Annika Lindblom1, Jan Lubinski1, Arto Mannermaa1, Sara Margolin1, Alfons Meindl1, Roger L Milne1, Taru A Muranen1, Polly A Newcomb1, Kenneth Offit1, Tjoung-Won Park-Simon1, Julian Peto1, Paul D P Pharoah1, Mark Robson1, Anja Rudolph1, Elinor J Sawyer1, Rita K Schmutzler1, Caroline Seynaeve1, Julie Soens1, Melissa C Southey1, Amanda B Spurdle1, Harald Surowy1, Anthony Swerdlow1, Rob A E M Tollenaar1, Ian Tomlinson1, Amy Trentham-Dietz1, Celine Vachon1, Qin Wang1, Alice S Whittemore1, Argyrios Ziogas1, Lizet van der Kolk1, Heli Nevanlinna1, Thilo Dörk1, Stig Bojesen1, Douglas F Easton1.   

Abstract

PURPOSE: CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. PATIENTS AND METHODS: CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies.
RESULTS: Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center-based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 × 10(-20)). The OR was higher for estrogen receptor (ER)-positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 × 10(-21)]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 × 10(-4)). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom.
CONCLUSION: These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27269948      PMCID: PMC5019754          DOI: 10.1200/JCO.2016.66.5844

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  CHEK2-positive breast cancers in young Polish women.

Authors:  Cezary Cybulski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Tadeusz Debniak; Dominika Wokolorczyk; Anna Jakubowska; Elzbieta Kowalska; Oleg Oszurek; Steven A Narod; Jan Lubinski
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

2.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Authors:  Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan Klijn; Ans van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

Review 3.  Chk1 and Chk2 kinases in checkpoint control and cancer.

Authors:  Jiri Bartek; Jiri Lukas
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

4.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.

Authors:  G H de Bock; M Schutte; E M M Krol-Warmerdam; C Seynaeve; J Blom; C T M Brekelmans; H Meijers-Heijboer; C J van Asperen; C J Cornelisse; P Devilee; R A E M Tollenaar; J G M Klijn
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

5.  The regulation of CHK2 in human cancer.

Authors:  Ashley L Craig; Ted R Hupp
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

6.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

Review 7.  Risk determination and prevention of breast cancer.

Authors:  Anthony Howell; Annie S Anderson; Robert B Clarke; Stephen W Duffy; D Gareth Evans; Montserat Garcia-Closas; Andy J Gescher; Timothy J Key; John M Saxton; Michelle N Harvie
Journal:  Breast Cancer Res       Date:  2014-09-28       Impact factor: 6.466

8.  Prediction of breast cancer risk based on profiling with common genetic variants.

Authors:  Nasim Mavaddat; Paul D P Pharoah; Kyriaki Michailidou; Jonathan Tyrer; Mark N Brook; Manjeet K Bolla; Qin Wang; Joe Dennis; Alison M Dunning; Mitul Shah; Robert Luben; Judith Brown; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Kamila Czene; Hatef Darabi; Mikael Eriksson; Julian Peto; Isabel Dos-Santos-Silva; Frank Dudbridge; Nichola Johnson; Marjanka K Schmidt; Annegien Broeks; Senno Verhoef; Emiel J Rutgers; Anthony Swerdlow; Alan Ashworth; Nick Orr; Minouk J Schoemaker; Jonine Figueroa; Stephen J Chanock; Louise Brinton; Jolanta Lissowska; Fergus J Couch; Janet E Olson; Celine Vachon; Vernon S Pankratz; Diether Lambrechts; Hans Wildiers; Chantal Van Ongeval; Erik van Limbergen; Vessela Kristensen; Grethe Grenaker Alnæs; Silje Nord; Anne-Lise Borresen-Dale; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Jenny Chang-Claude; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Peter A Fasching; Lothar Haeberle; Arif B Ekici; Matthias W Beckmann; Barbara Burwinkel; Frederik Marme; Andreas Schneeweiss; Christof Sohn; Amy Trentham-Dietz; Polly Newcomb; Linda Titus; Kathleen M Egan; David J Hunter; Sara Lindstrom; Rulla M Tamimi; Peter Kraft; Nazneen Rahman; Clare Turnbull; Anthony Renwick; Sheila Seal; Jingmei Li; Jianjun Liu; Keith Humphreys; Javier Benitez; M Pilar Zamora; Jose Ignacio Arias Perez; Primitiva Menéndez; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Natalia V Bogdanova; Natalia N Antonenkova; Thilo Dörk; Hoda Anton-Culver; Susan L Neuhausen; Argyrios Ziogas; Leslie Bernstein; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J van Asperen; Angela Cox; Simon S Cross; Malcolm W R Reed; Elza Khusnutdinova; Marina Bermisheva; Darya Prokofyeva; Zalina Takhirova; Alfons Meindl; Rita K Schmutzler; Christian Sutter; Rongxi Yang; Peter Schürmann; Michael Bremer; Hans Christiansen; Tjoung-Won Park-Simon; Peter Hillemanns; Pascal Guénel; Thérèse Truong; Florence Menegaux; Marie Sanchez; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Valeria Pensotti; John L Hopper; Helen Tsimiklis; Carmel Apicella; Melissa C Southey; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Alice J Sigurdson; Michele M Doody; Ute Hamann; Diana Torres; Hans-Ulrich Ulmer; Asta Försti; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Irene L Andrulis; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Georgia Chenevix-Trench; Rosemary Balleine; Graham G Giles; Roger L Milne; Catriona McLean; Annika Lindblom; Sara Margolin; Christopher A Haiman; Brian E Henderson; Fredrick Schumacher; Loic Le Marchand; Ursula Eilber; Shan Wang-Gohrke; Maartje J Hooning; Antoinette Hollestelle; Ans M W van den Ouweland; Linetta B Koppert; Jane Carpenter; Christine Clarke; Rodney Scott; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Hermann Brenner; Volker Arndt; Christa Stegmaier; Aida Karina Dieffenbach; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Kenneth Offit; Joseph Vijai; Mark Robson; Rohini Rau-Murthy; Miriam Dwek; Ruth Swann; Katherine Annie Perkins; Mark S Goldberg; France Labrèche; Martine Dumont; Diana M Eccles; William J Tapper; Sajjad Rafiq; Esther M John; Alice S Whittemore; Susan Slager; Drakoulis Yannoukakos; Amanda E Toland; Song Yao; Wei Zheng; Sandra L Halverson; Anna González-Neira; Guillermo Pita; M Rosario Alonso; Nuria Álvarez; Daniel Herrero; Daniel C Tessier; Daniel Vincent; Francois Bacot; Craig Luccarini; Caroline Baynes; Shahana Ahmed; Mel Maranian; Catherine S Healey; Jacques Simard; Per Hall; Douglas F Easton; Montserrat Garcia-Closas
Journal:  J Natl Cancer Inst       Date:  2015-04-08       Impact factor: 13.506

9.  Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.

Authors:  Olivia Fletcher; Nichola Johnson; Isabel Dos Santos Silva; Outi Kilpivaara; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Marijke Wasielewski; Hanne Meijers-Heijerboer; Annegien Broeks; Marjanka K Schmidt; Laura J Van't Veer; Michael Bremer; Thilo Dörk; Elena V Chekmariova; Anna P Sokolenko; Evgeny N Imyanitov; Ute Hamann; Muhammad U Rashid; Hiltrud Brauch; Christina Justenhoven; Alan Ashworth; Julian Peto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

10.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

Authors:  A J Lee; A P Cunningham; K B Kuchenbaecker; N Mavaddat; D F Easton; A C Antoniou
Journal:  Br J Cancer       Date:  2013-12-17       Impact factor: 7.640

View more
  45 in total

Review 1.  Germline Mutations in Triple-Negative Breast Cancer.

Authors:  Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2017-02-24       Impact factor: 2.860

2.  Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods.

Authors:  Lothar Häberle; Alexander Hein; Matthias Rübner; Michael Schneider; Arif B Ekici; Paul Gass; Arndt Hartmann; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Wing-Yee Lo; Werner Schroth; Hiltrud Brauch; Peter A Fasching; Marius Wunderle
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-06-28       Impact factor: 2.915

3.  Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data.

Authors:  Thomas Madsen; Danielle Braun; Gang Peng; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Genet Epidemiol       Date:  2018-06-25       Impact factor: 2.135

4.  A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations.

Authors:  Danielle Braun; Jiabei Yang; Molly Griffin; Giovanni Parmigiani; Kevin S Hughes
Journal:  J Genet Couns       Date:  2018-03-02       Impact factor: 2.537

5.  Identification of Rare Variants Predisposing to Thyroid Cancer.

Authors:  Yanqiang Wang; Sandya Liyanarachchi; Katherine E Miller; Taina T Nieminen; Daniel F Comiskey; Wei Li; Pamela Brock; David E Symer; Keiko Akagi; Katherine E DeLap; Huiling He; Daniel C Koboldt; Albert de la Chapelle
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

Review 6.  Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.

Authors:  Amanda B Spurdle; Michael A Bowman; Jannah Shamsani; Judy Kirk
Journal:  Mod Pathol       Date:  2017-04-28       Impact factor: 7.842

7.  Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mingming Liang; Yun Zhang; Chenyu Sun; Feras Kamel Rizeq; Min Min; Tingting Shi; Yehuan Sun
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

8.  Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer.

Authors:  Stephanie L Greville-Heygate; Tom Maishman; William J Tapper; Ramsey I Cutress; Ellen Copson; Alison M Dunning; Linda Haywood; Louise J Jones; Diana M Eccles
Journal:  JCO Precis Oncol       Date:  2020-05-04

Review 9.  Nipple-sparing mastectomy in women at high risk of developing breast cancer.

Authors:  Rebecca S Lewis; Angela George; Jennifer E Rusby
Journal:  Gland Surg       Date:  2018-06

Review 10.  Cancer genetics, precision prevention and a call to action.

Authors:  Clare Turnbull; Amit Sud; Richard S Houlston
Journal:  Nat Genet       Date:  2018-08-29       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.